Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

被引：27

作者：

Lundgren, Jens ^{[1
,2
]}

Babiker, Abdel ^{[3
]}

Gordin, Fred ^{[4
]}

Emery, Sean ^{[5
]}

Faetkenheuer, Gerd ^{[6
]}

Molina, Jean-Michel ^{[7
,8
]}

Wood, Robin ^{[9
,10
]}

Neaton, James D. ^{[11
]}

机构：

[1] Univ Copenhagen, Rigshosp, Dept Infect Dis, Copenhagen HIV Programme, DK-2100 Copenhagen O, Denmark

[2] Univ Copenhagen, Rigshosp, Ctr Hlth & Infect Dis Res, DK-2100 Copenhagen O, Denmark

[3] UCL, MRC Clin Trials Unit, London, England

[4] George Washington Univ, Vet Affairs Med Ctr, Washington, DC USA

[5] Kirkby Inst, Sydney, NSW, Australia

[6] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[7] Agence Natl Rech SIDA & Hepatites Virales ANRS, HIV AIDS Clin Trial Grp, Paris, France

[8] Univ Paris 07, St Louis Hosp, AP HP, Paris, France

[9] Univ Cape Town, Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa

[10] London Sch Hyg & Trop Med, London WC1, England

[11] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA

来源：

HIV MEDICINE | 2015年 / 16卷

关键词：

antiretroviral therapy; CD4-guided ART; HIV; START trial; when to start; ANTIRETROVIRAL TREATMENT; BASE-LINE; CLINICAL-OUTCOMES; CELL COUNTS; THERAPY; RISK; INFECTION; PARTICIPANTS; PREVALENCE; ENROLLMENT;

D O I：

10.1111/hiv.12227

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：1 / 9

页数：9

共 41 条

[1] Kidney disease in antiretroviral-naive HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial [J].

Achhra, A. C. ;

Mocroft, A. ;

Ross, M. J. ;

Ryom, L. ;

Lucas, G. M. ;

Furrer, H. ;

Neuhaus, J. ;

Somboonwit, C. ;

Kelly, M. ;

Gatell, J. M. ;

Wyatt, C. M. .

HIV MEDICINE, 2015, 16 :55-63

[2] Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study [J].

Babiker, Abdel G. ;

Emery, Sean ;

Faetkenheuer, Gerd ;

Gordin, Fred M. ;

Grund, Birgit ;

Lundgren, Jens D. ;

Neaton, James D. ;

Pett, Sarah L. ;

Phillips, Andrew ;

Touloumi, Giota ;

Vjecha, Michael J. .

CLINICAL TRIALS, 2013, 10 :S5-S36

[3] Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial [J].

Baker, J. V. ;

Engen, N. W. ;

Hullsiek, K. Huppler ;

Stephan, C. ;

Jain, M. K. ;

Munderi, P. ;

Pett, S. ;

Duprez, D. .

HIV MEDICINE, 2015, 16 :109-118

[4] Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial [J].

Baxter, J. D. ;

Dunn, D. ;

White, E. ;

Sharma, S. ;

Geretti, A. M. ;

Kozal, M. J. ;

Johnson, M. A. ;

Jacoby, S. ;

Llibre, J. M. ;

Lundgren, J. .

HIV MEDICINE, 2015, 16 :77-87

[5] Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease [J].

Borges, Alvaro H. ;

Weitz, Jeffrey I. ;

Collins, Gary ;

Baker, Jason V. ;

Levy, Yves ;

Davey, Richard T., Jr. ;

Phillips, Andrew N. ;

Neaton, James D. ;

Lundgren, Jens D. ;

Deeks, Steven G. .

AIDS, 2014, 28 (12) :1791-1796

[6] Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers [J].

Borges, Alvaro H. ;

Silverberg, Michael J. ;

Wentworth, Deborah ;

Grulich, Andrew E. ;

Faetkenheuer, Gerd ;

Mitsuyasu, Ronald ;

Tambussi, Giuseppe ;

Sabin, Caroline A. ;

Neaton, James D. ;

Lundgren, Jens D. .

AIDS, 2013, 27 (09) :1433-1441

[7] Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy (ART) Are Associated With Increased Risk of AIDS or Death [J].

Boulware, David R. ;

Hullsiek, Katherine Huppler ;

Puronen, Camille E. ;

Rupert, Adam ;

Baker, Jason V. ;

French, Martyn A. ;

Bohjanen, Paul R. ;

Novak, Richard M. ;

Neaton, James D. ;

Sereti, Irini .

JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (11) :1637-1646

[8] When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries An Observational Study [J].

Cain, Lauren E. ;

Logan, Roger ;

Robins, James M. ;

Sterne, Jonathan A. C. ;

Sabin, Caroline ;

Bansi, Loveleen ;

Justice, Amy ;

Goulet, Joseph ;

van Sighem, Ard ;

de Wolf, Frank ;

Bucher, Heiner C. ;

von Wyl, Viktor ;

Esteve, Anna ;

Casabona, Jordi ;

del Amo, Julia ;

Moreno, Santiago ;

Seng, Remonie ;

Meyer, Laurence ;

Perez-Hoyos, Santiago ;

Muga, Roberto ;

Lodi, Sara ;

Lanoy, Emilie ;

Costagliola, Dominique ;

Hernan, Miguel A. .

ANNALS OF INTERNAL MEDICINE, 2011, 154 (08) :509-515

[9] Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial [J].

Carr, A. ;

Grund, B. ;

Neuhaus, J. ;

Schwartz, A. ;

Bernardino, J. I. ;

White, D. ;

Badel-Faesen, S. ;

Avihingsanon, A. ;

Ensrud, K. ;

Hoy, J. .

HIV MEDICINE, 2015, 16 :137-146

[10] Prevention of HIV-1 Infection with Early Antiretroviral Therapy [J].

Cohen, Myron S. ;

Chen, Ying Q. ;

McCauley, Marybeth ;

Gamble, Theresa ;

Hosseinipour, Mina C. ;

Kumarasamy, Nagalingeswaran ;

Hakim, James G. ;

Kumwenda, Johnstone ;

Grinsztejn, Beatriz ;

Pilotto, Jose H. S. ;

Godbole, Sheela V. ;

Mehendale, Sanjay ;

Chariyalertsak, Suwat ;

Santos, Breno R. ;

Mayer, Kenneth H. ;

Hoffman, Irving F. ;

Eshleman, Susan H. ;

Piwowar-Manning, Estelle ;

Wang, Lei ;

Makhema, Joseph ;

Mills, Lisa A. ;

de Bruyn, Guy ;

Sanne, Ian ;

Eron, Joseph ;

Gallant, Joel ;

Havlir, Diane ;

Swindells, Susan ;

Ribaudo, Heather ;

Elharrar, Vanessa ;

Burns, David ;

Taha, Taha E. ;

Nielsen-Saines, Karin ;

Celentano, David ;

Essex, Max ;

Fleming, Thomas R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (06) :493-505

← 1 2 3 4 5 →